ACRS - NASDAQ

Aclaris Therapeutics, Inc.

ACRS·NASDAQ

$4.42

-4.5%

HealthcareBiotechnology

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$533.03M

EPS-0.5300

P/E Ratio-8.34

Earnings Date08/06/2026

160.46M

Assets

-27%

3Y-37.0%

5Y+127.0%

10Y-9.0%

57.38M

Total Liabilities

-11%

3Y+1.0%

5Y+73.0%

10Y+770.0%

103.08M

Total Equity

-34%

3Y-48.0%

5Y+174.0%

10Y-39.0%

Aclaris Therapeutics, Inc. Funding & Solvency Profile

ACRS · NASDAQ

Current Assets

Cash & Cash Equivalents19.96M

Net Receivables5.57M

Inventory0.00

Other Current Assets55.05M

Total Current Assets151 M

Non-Current Assets

Property, Plant & Equipment0.00

Goodwill & Intangible Assets0.00

Long-Term Investments60.61M

Other Non-Current Assets-51.52M

Total Non-Current Assets9 M

Total Assets

160.46M

Financial Health Analysis

Current Ratio

5.28x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.56x

Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.

Working Capital

123 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

94% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Aclaris Therapeutics, Inc. Balance Sheet

ACRS • NASDAQ

Aclaris Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	20M	24.6M	39.9M	45.3M	27.3M	22.1M	35.9M	57M	208.9M	30.2M	9.9M	10.8M	9.6M
Short-Term Investments	70.8M	89M	79.2M	172.3M	164.1M	32.1M	39.1M	111M	173.7M	107.1M	75M	5.4M	3.7M
Cash & Short-Term Investments	90.8M	113.6M	119.1M	217.6M	191.4M	54.1M	75M	168M	208.9M	174.1M	92M	16.1M	13.3M
Net Receivables	5.6M	318K	298K	484K	623K	772K	704K	563K	481K	0.0	0.0	0.0	0.0
Accounts Receivables	5.6M	318K	298K	484K	623K	772K	704K	563K	481K	0.0	0.0	0.0	0.0
Inventory	0.0	0.0	0.0	0.0	0.0	0.0	5M	791K	-6.4M	0.0	0.0	0.0	0.0
Prepaids	0.0	0.0	0.0	0.0	13M	2.6M	3.1M	4.8M	3.9M	1.3M	1.4M	204K	62K
Other Current Assets	55M	12M	9.5M	13.5M	0.0	0.0	0.0	5.4M	5.9M	1.3M	1.7M	0.0	0.0
Total Current Assets	151.4M	126M	128.9M	231.6M	205M	57.5M	83.8M	179.5M	208.9M	174.1M	92M	16.3M	13.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	0.0	1M	1.6M	1.1M	1.3M	1.7M	2.5M	4.3M	2.2M	481K	360K	515K	19K
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.5M	18.5M	0.0	0.0	0.0	0.0
Intangible Assets	0.0	0.0	269K	7M	7M	7.1M	7.2M	73M	7.3M	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	0.0	0.0	269K	7M	7M	7.1M	7.2M	91.5M	25.9M	0.0	0.0	0.0	0.0
Long-Term Investments	60.6M	90.3M	62.8M	12.2M	34.2M	0.0	0.0	0.0	15M	36.9M	7.2M	518K	802K
Tax Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-8.6M	0.0	0.0	0.0	0.0
Other Non-Current Assets	-51.5M	3.1M	3.9M	2.7M	3.6M	4.5M	4.8M	332K	279K	-35.4M	-5.5M	10K	0.0
Total Non-Current Assets	9.1M	94.4M	68.5M	23M	46.2M	13.3M	14.5M	96.1M	34.7M	2M	2M	1M	821K
Total Assets	160.5M	220.3M	197.4M	254.6M	251.2M	70.8M	98.3M	275.6M	243.5M	176.1M	94.1M	17.4M	14.2M
LIABILITIES
CURRENT LIABILITIES
Total Payables	13.2M	4.7M	8.9M	10.4M	10M	5.3M	9.9M	11.7M	7.8M	2.8M	810K	1.3M	353K
Accounts Payable	13.2M	4.7M	8.9M	10.4M	10M	5.3M	9.9M	11.7M	7.8M	2.8M	810K	1.3M	353K
Accrued Expenses	0.0	11.4M	15.5M	3.4M	5.7M	1.9M	4.4M	8.1M	4.8M	3.3M	745K	188K	14K
Short Term Debt	551K	0.0	0.0	0.0	0.0	0.0	637K	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	0.0	426K	684K	693K	603K	637K	142K	142K	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	3.9M	0.0	0.0	0.0	0.0	7.7M	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	14.9M	11.6M	6.1M	7.5M	6.6M	7.1M	-880K	7.4M	0.0	100K	0.0	0.0	0.0
Total Current Liabilities	28.6M	31.6M	31M	21.9M	22.9M	14.9M	22.4M	27.3M	12.8M	6.2M	1.6M	1.5M	367K
NON-CURRENT LIABILITIES
Long Term Debt	0.0	0.0	0.0	0.0	0.0	10.7M	0.0	29.9M	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	16.2M	20M	0.0	0.0	0.0	0.0	-3.6M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Tax Liabilities (Non-Current)	0.0	0.0	0.0	367K	367K	367K	549K	549K	549K	0.0	0.0	0.0	0.0
Other Non-Current Liabilities	11M	13.1M	9.3M	34.7M	30.6M	7.2M	5.4M	2.6M	4.9M	372K	0.0	36.7M	23M
Total Non-Current Liabilities	28.7M	33.2M	9.3M	35M	30.9M	18.3M	6M	33.1M	5.5M	372K	0.0	36.7M	23M
Capital Lease Obligations	1.6M	0.0	426K	684K	693K	603K	637K	601K	142K	0.0	0.0	0.0	0.0
Total Liabilities	57.4M	64.8M	40.2M	57M	53.9M	33.1M	28.4M	60.4M	18.2M	6.6M	1.6M	38.1M	23.4M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	94.1M	36.7M	23M
Common Stock	1K	1K	1K	1K	1K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Additional Paid-In Capital	1.1B	1.1B	928.1M	880.8M	793M	542.3M	523.5M	507.4M	384.9M	260.7M	135.5M	0.0	0.0
Retained Earnings	-967.8M	-902.9M	-770.8M	-682.3M	-595.4M	-504.5M	-453.5M	-292.2M	-159.4M	-90.9M	-42.8M	-20.7M	-9.2M
Accumulated Other Comprehensive Income/Loss	610K	97K	-106K	-897K	-224K	-94K	-66K	-69K	-246K	-269K	-149K	-6K	3K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	-36.7M	-23M
Total Stockholders' Equity	103.1M	155.6M	157.2M	197.6M	197.3M	37.7M	69.9M	215.1M	225.3M	169.5M	92.5M	-20.8M	-9.2M
Total Equity	103.1M	155.6M	157.2M	197.6M	197.3M	37.7M	69.9M	215.1M	225.3M	169.5M	92.5M	-20.8M	-9.2M
SUMMARY
Total Liabilities & Equity	160.5M	220.3M	197.4M	254.6M	251.2M	70.8M	98.3M	275.6M	243.5M	176.1M	94.1M	17.4M	14.2M
Total Investments	131.4M	179.3M	142M	184.5M	198.3M	32.1M	39.1M	111M	188.7M	144M	82.2M	5.9M	4.5M
Total Debt	2.1M	0.0	426K	684K	693K	11.3M	637K	30.5M	142K	0.0	0.0	0.0	0.0
Net Debt	-17.8M	-24.6M	-39.5M	-44.6M	-26.7M	-10.8M	-35.3M	-26.5M	-208.7M	-30.2M	-9.9M	-10.8M	-9.6M
Shares Outstanding	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218	108,332,218

SEC Filings

ACRS - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 07, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 07, 2026	May 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 28, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 23, 2026	June 04, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 11, 2026	March 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 10, 2026	March 09, 2026	2026	View Filing
10-K 10-K 2025 FY FY	February 26, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	February 26, 2026	February 26, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 12, 2026	January 12, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 06, 2026	January 06, 2026	2026	View Filing

Showing 1 to 10 of 215 filings

Related Guides

Blog Categories

Continue your ACRS research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.